Articles, insights, and posts about Child Development, early detection, and new methods in diagnosis and treatment.
In São Paulo, Brazil, we had the opportunity to get a few moments of Dr. Thais Arbocese Zanolla’s busy schedule to discuss how she uses Face2Gene in her genetics practice, where the app helps her and where it does not. As she explained it to us, Face2Gene helps her save valuable time during consultation and […]
Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this link> Dr. Christine Stanley, Head of Clinical Laboratory for WuXi NextCODE, US and CLIA medical director for Q&A Diagnostics, discusses next-generation phenotyping for improved variant interpretation through integration of Face2Gene LABS with WuXi NextCODE’s variant interpretation […]
Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this link> HISTORY Since the 1960s, the field of medical genetics has been evolving rapidly with regard to phenotype delineation and analysis. A disease phenotype requires a multi-faceted analysis. Besides defining the phenotype with diagnostic criteria, […]
Note: This talk was presented at the 2018 ACMG annual meeting. The video can be seen below, or at this link> Starting in 1996, a select few clinicians began identifying a small group of patients with similar phenotypic features: Down-syndrome-like facial features, short stature, intellectual disability, cataracts and sensorineural hearing loss. Among these clinicians was […]
FDNA’s CEO, Dekel Gelbman, joined two distinguished members of the genetics community—Dr. John Carey (University of Utah) and Dr. Christine Stanley (WuXi NextCODE)—on redefining phenotyping for clinical advancements and variant prioritization. Dr. Carey. a highly-practiced clinician, currently at the University of Utah’s Department of Medical Genetics, kicked off the webinar with a comprehensive background on […]
HIMSS Conference, Microsoft booth Thursday, March 7 3:40 PM PST Las Vegas, Nevada As over 40,000 health IT professionals, clinicians, executives, and vendors from around the world gather at this year’s HIMSS Annual Conference & Exhibition, speaker Anthony Antonuccio, VP of Product at FDNA shares FDNA’s experience with one of the leading clinics, Greenwood Genetic […]
English | Spanish In a packed auditorium at Mexico City’s CENTRO University, FDNA’s Senior Director of Marketing, Jeff Daniels, announced the launch of the Genomics Collaborative. This initiative prompts clinicians, patients, advocates and researchers to join forces in an effort to accelerate breakthroughs in precision medicine. The Genomics Collaborative allows participants to access FDNA’s deep […]
At FDNA, we’re making precision medicine a reality by crowdsourcing knowledge and integrating next-generation phenotyping (NGP) technologies into every patient evaluation. NGP is the computational capture, analysis and integration of phenotypic data into health analysis—a hallmark of FDNA’s technologies. In 2017, our Face2Gene application turned five, and alongside our collaborators, we marked some serious milestones: […]
In an era of breakthrough advancements in healthcare, it is hard to believe that 90% of blockbuster medicines are only effective for 30-50% of patients. The reason? A “one-size-fits-all” approach to pharmaceutical development and commercialization. At this year’s 22nd Annual Drug Delivery Partnership meeting, a new approach to the pharma value chain is in discussion. […]